SCHEMBL2872116

SCHEMBL2872116

O=C(c1ccc(O)c(Cc2ccc(Oc3ccccc3)cc2)c1)P(=O)(O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 5/20 0.52
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
MMP2 P08253 1/20 0.45
CA9 Q16790 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
SLC7A5 Q01650 1/20 0.42
MAPK14 Q16539 3/20 0.42
HPGD P15428 2/20 0.41
FFAR1 O14842 1/20 0.40
CYP3A4 P08684 1/20 0.40
ALOX15 P16050 1/20 0.40
HIF1A Q16665 1/20 0.40
HSD17B10 Q99714 1/20 0.40
BCL2 P10415 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2874029 0.94 SRD5A2 (0.46) SRD5A2CA12CA1CA2MMP2
SCHEMBL2866515 0.92 SRD5A2 (0.45) SRD5A2CA12CA1CA2MMP2
SCHEMBL2867645 0.85 PLK1 (0.42) CA1CA2ALOX15
SCHEMBL2859683 0.83 KEAP1 (0.45) MEN1KMT2ASLC7A5HPGDCYP3A4
SCHEMBL2872134 0.82 MAPT (0.47) HPGDALOX15HSD17B10PARP10
SCHEMBL2871484 0.82 SRD5A2 (0.47) SRD5A2CA12CA1CA2MMP2
SCHEMBL2872127 0.82 SMN1; SMN2 (0.46) SRD5A2CA12CA1CA2MMP2
SCHEMBL2870973 0.82 SRD5A2 (0.46) SRD5A2CA12CA1CA2MMP2
SCHEMBL2869093 0.81 POLB (0.43) KMT2ASLC7A5HPGDPARP10
SCHEMBL2871495 0.81 GAA (0.42) SLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691898-B2 Phosphonic acid derivatives and the treating agents of diseases related hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
CN-101072783-A Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates KOTOBUKI PHARMACEUTICAL CO LTD (JP) 2007-11-14 CN disclosed
EP-1813620-A1 PHOSPHONIC ACID DERIVATIVE AND THERAPEUTIC AGENT FOR DISEASE IN WHICH HIGH PHOSPHATE LEVEL IN BLOOD PARTICIPATES Kotobuki Pharmaceutical Co., Ltd. (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119441-A1 Phosphonic Acid Derivatives and the Treating Agents of Diseases Related Hyperphosphatemia NR0B1, NR0B2, PTH1R SRD5A2 69/4885CA12 797/4885CA1 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.